Você está na página 1de 94

1

WORKSHOP May 20th 2013 ACQUA PER USO FARMACEUTICO


Speaker Pasquale Della Valle
ELETTRACQUA Technical and Sales Manager

2
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

AGENDA
1. Introduzione 2. Opzioni di Pretrattamento 3. Opzioni di Trattamento Finale 4. Stoccaggio e Distribuzione 5. Validazione 6. Comparison Compendial Water ANVISA vs USP35 and EP7th Ed.

INTRODUCTION

1. INTRODUZIONE

4
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE

La selezione della qualit necessaria per l'acqua o vapore puro

potenzialmente la fase pi critica


nella pianificazione di un nuovo progetto di produzione di acqua per uso farmaceutico o sistema di vapore puro, da un punto di vista normativo, tecnico e finanziario.

5
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE

Luso dellAcqua nel settore farmaceutico include le seguenti applicazioni : - Come ingrediente nella formulazione di specialit farmaceutiche - Come ingrediente nella produzione di principi attivi (API) - Come risciacquo finale durante Clean in Place (CIP) delle apparecchiature di produzione - Come solvente o diluente per i processi di ricerca o di laboratorio

6
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE
Il design,costruzione,commissioning e validazione del sistema acqua per lindustria farmaceutica rappresenta una importante sfida poich deve essere conforme alle prescrizioni delle cCMP,oltre che rispettare tutte le leggi e le regolatorie locali.

WATER OPTIONS:I requisiti qualitativi delle acque impiegate nelle produzioni farmaceutiche sono guidate dalle caratteristiche del prodotto.Le monografie ufficiali(USP e EU) definiscono I requisiti minimi per ciascun tipo dacqua.In ogni caso la scelta finale della qualit dellacqua in relazione allimpiego al quale destinata,resta di specifica responsabilitt della Azienda Farmaceutica . Le acque di uso farmaceutico sono divise in due categorie: Compendial water e Non compendial water

7
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE

Le pharmacopee pi importanti: United States Pharmacopoeia (USP), European Pharmacopoeia (EP) Japanese Pharmacopoeia (JP) Definisco due Compendial Water and Steam

Purified Water (PW) Water far Injection (WFI) Pure Steam (PS) Highly Purified Water(HPW),EU only

8
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE

PHARMACEUTICAL WATER QUALITY DECISION TREE

9
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE

Il controllo di tutti i parametri critici di processo sono necessari, quando possono avere diretta conseguenza sul prodotto finale. I requisiti minimi per i metodi di produzione, la qualit dell'acqua di alimentazione, e gli attributi di qualit per le acque compendial sono definite nelle specifiche monografiche.

10
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

INTRODUZIONE

La figura mostra la GUIDE LINE utile nel processo decisionale, nella definizione iniziale della tipologia di acqua necessaria e quindi determinare il progetto del sistema necessario dal pretrattamento al trattamento finale.

11

INTRODUCTION

2. PRETREATMENT OPTION

12
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Pretrattamento viene definito linsieme di tutte le fasi di trattamento necessarie a garantire che la qualit dell'acqua di alimentazione diventi di qualit adeguata ad ottimizzare le prestazioni del trattamento finale.Esse sono definiti nei seguenti step.

Control of fouling :rimozione della torbidit e colloidi


Control of scaling :rimozione o controllo della durezza e metalli
Control of Organics:riduzione delle sostanze organiche e batteriche

13
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Control of fouling :rimozione della torbidit e particolati TORBIDITA


causata da materiale in sospensione e colloidale, che pu essere di natura organica o inorganica ed altri microorganismi .

PARTICOLATI
Tipicamente sono minerali insolubili. In particolare silice coloidale.

14
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

La rimozione della torbidita e particolato fondamentale per evitare lo sporcamento dello step finale del trattamento, in particolare lintasamento delle membrane di Osmosi Inversa

I metodi pi utilizzati per rimuovere TORBIDITA E PARTICOLATO,sono: Filtrazione multimedia Ultrafiltrazione

la

15
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

FILTRATION SPECTRUM

16
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION
Filtrazione Dualmedia :sono formati da contenitori in pressione,con allinterno materiale filtrante formato da quarzite e carbone antracite.

Advantage:

Large capacity per unit cost Low cost of operation

Disadvantage:

Particle reduction limited to 10m (approx)

Can become a source of microbiological contamination if improperly maintained, designed or operated

17
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Ultrafiltration
Vantaggi :
La Ultrafiltrazione una barriera invalicabile per tutti microorgnismi (virus e batteri) e tutti quei composti che formanno la torbiditt oltre che per la totalitt dei colloidi. Lefficacia del processo della filtrazione indipendente della caratteristica dellacqua di alimentazione. UF pore rating : 1000-100,000 Daltons cut-off. UF membrane sono in polysulfone in configurazione fibra cava(hollow fiber). UF membrane hanno pori di filtrazione in un range 0,01-0,1 microns.

18
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

VANTAGGI DELLA ULTRAFILTRAZIONE Rispetto ai processi di trattamento convenzionale: Alcune particelle colloidali hanno una dimensione inferiore 0,2 micron (per essempio silice colloidale) Quindi non sono trattenute dal dual media filter che limitato a circa 10m, ne dalla filtrazione a cartuccia. E hanno un impatto drammatico sulla membrana di RO causando un rapido sporcamento e il fuori servizio. Fasi di trattamento successive avranno maggiore efficienza e affidabilit dovuta al fatto che tutta la torbidita ed i colloidi saranno stati completamente eliminati. .

19
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

CASE STUDY: Laboratrio Teuto Brasileiro


PROBLEMATICHE RILEVATE SULL IMPIANTO PRE ESISTENTE,FORNITO DA ALTRO SUPPLIER DA 7/8 ANNI
PROBLEMATICHE DELLACQUA DI ALIMENTAZIONE TORBIDITA: 0.22-11.1 NTU INDICE DEI COLLOIDI: SDI O,3-8 IL PARTICOLATO COLLOIDALE PASSA SIA IL DUALMEDIA FILTER E IL FILTRO A CARTUCCIA

IMPATTANDO DRAMMATICAMENTE SULLE MEMBRANE DI OSMOSI INVERSA CAUSANDO LA

Sostituizione delle membrane circa 6 mesi con notevole costo di essercicio e fuori servizio di produzione

20
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION
DRAMATICALLY IMPACT on the RO Performance reduction of capacity of PW production high frequency of cleaning reduction of RO membrane life: replacement every 6/8 months ELETTRACQUA HA FORNITO NEL 2011 UN NUOVO IMPIANTO DI PRODUZIONE WFI,REALIZZATO CON MEMBRANE DI RO.IL SISTEMA DI PRETRATTAMENTO E STATO PROGETTATO CON UF LACQUA PRETRATTATA INVIATA AL PRIMO PASSO DI RO HA I SEGUENTI PARAMETRI CHIMICO FISICI: Turbidity: less 0.1 NTU SDI: less 0.1 UN ANNO DI FUNZIONAMENTO SENZA NESSUN CLEANING CHIMICO DELLE MEMBRANE.VIENE CONFERMATO IL LIFE TIME DELLE MEMBRANE DI RO NON INFERIORE A 5 ANNI.

IN SEGUITO A QUESTI RISULTATI TEUTO HA COMMISSIONATO LA INSTALLAZIONE DI UN NUOVO SISTEMA DI UF A MONTE DEL VECCHIO IMPIANTO DI PW

21
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION In both the plant Elettracqua has supply DOW UF modules that utilize a double-walled hollow fiber H-PVDF membrane with a very small pore diameter (0,03 nominal pore) for excellent removal of particulate matter and bacteria, and most viruses and colloids.

22
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

IN IN

BACTERIA

FILTRATE

VIRUS

PROCESS OPERATIONS

Filtration Step Outside-In flow configuration for high tolerance to feed solids UF is operated at a constant permeate flow. The transmembrane pressure (TMP) will naturally increase over time, and the module can be cleaned by back-washing and air-scouring to remove the fouling layer for longer service life.

23
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION
Backwash (BW) Step Clean In Place Cleaning (CIP) Step

Cleaning Step The frequency of the cleaning step dependent on the feed water quality

Chemically Enhanced Backwash (CEB) step

Air Scour Step

24
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Control of scaling :controllo della durezza


Il controllo della durezza(Ca+Mg) necessario per evitare la precipitazione di composti incrostanti,come carbonati sulle membrane di Osmosi Inversa.

I sistemi di controllo includono METHODS of CONTROL include :

- Addolcimento con resine a scambio ionico - Dosaggio di prodotti antiprecipitanti(antiscalant)

25
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Softening by Ion Exchange


Ion exchange resins reduce the hardness by replacing magnesium and calcium with sodium
Ca2+, Mg2+, Na+, K+ HCO3-, Cl-, NO3-, SO42-, SiO2

NaCl 10 %

SAC

Na+, HCO3-, Cl-, NO3-, K+ , SO42-, SiO2

Regenerant Waste

26
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Softening by Ion Exchange


Softening by Ion Exchange is a very popular pretreatment step, but in case of low hardness content it is easy to control the hardness by Antiscalant Dosing before the 1st Pass RO

The typical Brazilian Raw Water analysis shows: low hardness: less 50ppm as CaCO3 low TDS high Turbidity (TSS, heavy metal and colloids, specially colloid silica)

27
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

Antiscalant Dosing
LAntiscalant sono dei composti chimici organofosfonati, a elevatissimo peso molecolare

APPROVATI by FDA-EPA-EP-WHO

Lantiscalant, dosato in piccola quantitt in acqua di alimentazione (3-5 mg/L) vanno chimicamente a legarsi al calcio, magnesio, ferro e silice in forma ionica - elevando il loro prodotto di solubilitt,quindi questi composti chimici,restano perfettamente in soluzione nellacqua e vengono totalmente rigettati delle membrane di Osmosi Inversa senza che vengono contaminate

28
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

SANITIZAZIONE
I necessarie metodi di santizazione per evitare eccessiva crescitt microbica sono : Sanitizazione chimica,oppure termica Controllo di Temperatura,a valori inferiori a 18C
Periodic Hot Water Sanitization Temperatures above 80C result the complete killing of all nonresistant bacteria.

> 80C

15C

Operating Temperatures below 15C avoid the bacterial growth

29
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

DEBATERIZAZIONE RAGGI ULTRAVIOLETTI (UV)

The UV light, 254 nm wavelength, deactivates DNA in the microorganisms, preventing duplication and leading to a reduction in bacteria. The feed water to a UV system needs to be free of suspended solids, which can "shadow" bacteria, preventing adequate UV contact. UV lights can not be used as sole means of microbial or organic contaminant control, but must be as a part of a total microbial control plan.

30
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

IPOCLORITO DI SODIO
Municipalities frequently use chlorine, often introduced as sodium hypochlorite to disinfect water before and during distribution.

Chlorine is fed into the system to kill bacteria at typical dosage levels of 0.2 ppm to 2.0 ppm.
Chlorine concentration should be monitored in the feed water and in parts of the pretreatment system prior to its removal.

31
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

PRETREATMENT OPTION

IPOCLORITO DI SODIO Deve essere totalmente eliminato prima di alimentare le membrane di Osmosi Inversa, che essendo di materiale Poliamide vereberro iremediabilmente ossidate.
PRINCIPALI SISTEMI DI RIMOZIONE IPOCLORITO DI SODIO:
Activated Carbon Reduction with Sodium Bisulfate dosing

32

INTRODUCTION

3. FINAL TRATMENT OPTIONS

33
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

PW, HPW and Non-compendial water can be produce by an extensive combination of unit processes in various combination as
membrane degasification (CO2 removal) Ultrafiltration microfiltration ultraviolet light Reverse Osmosis Electrodeionization

The most common PW system design implement a Single Reverse Osmosis Pass with

another Reverse Osmosis Pass RO + RO

or

a continuous electrodeionization stage RO + EDI

34
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

REVERSE OSMOSIS
Utilizing semi-permeable membrane, means that the membrane is permeable for water while impermeable for salts, acids, bases, colloids, bacteria and endotoxins. For Pharmaceutical water production, RO membrane have a spiral wound configuration and are available in cellulose acetate or thin film composite (polyamide). The majority of pharmaceutical systems utilize thin film composite membranes. The optimum membrane selection is based upon an analysis of capital cost, operating cost, membrane life, rejection and bacteria control.
PERMEATE FLOW CONCENTRATE

PERMEATE
CONCENTRATE

Advantages highest rejection of contaminants operate effectively at lower temperatures (4C and higher) operate effectively at low pressure (7 bar g and higher) longer life expectancy Disadvantages higher initial capital cost low tolerance for chlorinated feed water

FEED WATER

35
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

REVERSE OSMOSIS LIMITATIONS

RO cannot remove 100% of contaminants from water and has either very low or no capacity for the removal of several extremely low molecular weight dissolved organics. A concentrate flow is essential to remove the contaminants that are rejected by the membrane. The waste stream from an RO unit may be used for cooling tower make-up water or compressor cooling water, etc.

Recovery is defined as the percentage of feed water that becomes purified product water. Recovery can range from 20% (or less) up to 90%, depending on factors such as: feed water quality provided to the RO unit system capacity/configuration life cycle costs requirements A recovery unit with a high percentage output may have less waste to achieve the desired output rate, but will tend to have higher maintenance costs due to the fouling/scaling effects of the concentrate.
Produced water quality is dependent but not limited to membrane type, operating pressure, feed water quality.

36
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

Carbon dioxide pass directly through an RO membrane and will be in the RO product stream at the same level as that in the feed water stream. Carbon dioxide in the RO product stream may increase the product conductivity beyond the PW Stage 1 conductivity limit. To reduce these potential issues, a degasification unit operation could be added before or after the RO process.

37
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

HYDROPHOBIC HOLLOW FIBER MEMBRANE


The purpose is to remove the carbon dioxide (CO2)

Water on one side and strip gas on the other. The strip gas can be drawn by vacuum or pressurized on the inlet.
The strip gas lowers the partial pressure of the gas phase which causes the gases from the liquid phase to diffuse through the membrane into the gas phase.

Liquid Inlet

Advantages simple design and maintenance chemical free method simple installation low operation costs

Disadvantages more expensive than sodium hydroxide dosing

38
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

SODIUM HYDROXIDE DOSING SYSTEM


In case of feed water CO2 value lower than 10ppm Raising the pH value to 8.3, is possible to convert the Carbon Dioxide to Bicarbonate, which is more readily rejected by the RO membrane.

39
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

RO PRETREATMENT REQUIREMENTS
SCALING MINIMIZATION Scaling is possible since the feed water contaminants are being concentrated into waste water. Scale control is normally prevent by Using of water softening upstream of the membranes Injection of acids to lower the pH of feed water stream Dosing an antiscalant compound to prevent precipitation of dissolved ions
FOULING MINIMIZATION RO membrane fouling is reduced through the use of back-washable filters (multi-media, cartridge and ultrafiltration) and various microbial control pretreatment methods to reduce biological fouling OXIDATION MINIMIZATION The main causes of membrane degradation are oxidation of certain membrane materials and heat degradation. Thin film composite membrane system incorporate various compound for dechlorination, while protection against high temperature is normally incorporated where membrane material cannot tolerate high temperature.

40
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

RO PERFORMANCE
Single pass RO typically reduce the contaminants more than 99%, but produced water dont meet the conductivity requirements of most compendial PWs Double pass RO can produce water than can pass the Stage 1 conductivity requirements. Membrane selection should be based upon: Pre-treatment requirements Operating performance characteristics Sanitization options Warranties Capital and operating costs Feed water source

RO unit should incorporate sufficient membrane area for reliable operation. On of the most important factors to optimize this are is fouling and scaling potential understanding. The Silt Density Index (SDI) reading gives an indication of the tendency of feed water to foul the membranes. Lower SDI means low membrane cleaning frequency. SDI optimal value is 3 RO system typically are designed at a specific operating temperature and pressure; any deviations from the baseline condition could changes the amount or the quality of produced water.
Ex. An increase in temperature above the design temperature could lead to increase permeate flow, but potentially decrease product water quality due increasing salts passage in the permeate.

41
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

CONTROL AND INSTRUMENTATION


Proper instrumentation for monitoring and controlling critical and non-critical parameters of operation is essential to any RO system design. The product water quality from RO system is directly related to the feed water quality.

The most important parameters to control and measure are

FEED WATER
TEMPERATURE PRESSURE

PRODUCED WATER
CONDUCTIVITY TEMPERATURE PRESSURE FLOW RATE

WASTE WATER
FLOW RATE PRESSURE

42
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

REVERSE OSMOSIS CONCENTRATE REUSE


Pretreated Water 4,2 m3/h BREAK TANK FIRST PASS RO = 75% 3,5 m3/h SECOND PASS RO = 85% 0,5 m3/h

TOTAL RECOVERY = 71,4%

4,7

m3/h

3 m3/h

1,2 m3/h 0,5 m3/h

RO DOUBLE PASS SYSTEM WITHOUT CONCENTRATE RECOVERY SYSTEM (CRS)

43
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER


Pretreated Water 3,42 m3/h BREAK TANK FIRST PASS RO = 75% 3,5 m3/h SECOND PASS RO = 85%

1,28 m3/h

TOTAL RECOVERY = 87,7%

4,7

m3/h

3 m3/h

1,2 m3/h

0,5 m3/h

CONCENTRATE RECOVERY SYSTEM

= 65% 0,42 m3/h

0,78 m3/h

1,28 m3/h

RO DOUBLE PASS SYSTEM WITH CONCENTRATE RECOVERY SYSTEM (CRS)

44
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER


Differential pressure exceeding 2,5 bar Salt passage increasing Product flow rate decreasing

RO MEMBRANE CLEANING IS NEEDED


CHEMICAL CLEANING Carry out by chemical cleaners Acid based cleaners to remove metals and salts Alkaline cleaners to remove silt and organic foulants Dedicated tank and pump are needed THERMAL CLEANING Carry out by Hot Water at 85C Specially constructed membranes are needed

45
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER ION EXCHANGE RESINS ION SELECTIVE MEMBRANE

+ +

ELECTRICAL FIELD
to continuously remove ionized species and regenerate the resins

=
CONTINUOUS ELECTRODEIONIZATION CEDI
Continuous, not in batch or intermittent Ionic transport properties of the ion exchange are primary sizing parameter

46
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER


Ionized species are drawn from the water passing alone the ion depleting cells and transferred into concentrate water stream passing across the ion exchange membranes that are permeable to ionized species and not to water. Power supply create a Direct Current electric field between cathode and anode that contributes to the ionic transport far.
Concentrate Concentrate Concentrate Concentrate

PURIFIED WATER

PURIFIED WATER

Purifying Compartment

Concentrate compartment

High voltage cause water splitting into H+ and OH- that regenerate continuously the cationic and anionic exchange. This continuous high regeneration level, allows the consistent production of high purified water. CEDI is commonly used after RO unit in order to produce water with low conductivity and organic levels, RO+CEDI system may produce water with conductivity 0,1 S/cm or lower. CEDI unit performance is a function of feed water quality.

ANODE

PURIFIED WATER

CATODE

FEEDING WATER

47
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS - NON-COMPENDIAL WATER and COMPENDIAL PURIFIED WATER

ULTRAVIOLET LIGHT TREATMENT


for Polishing and Removal of specific contaminants

UV light treatment aims to decrease the bacteria growth inside the treated water

UV wavelengths and intensity level required depend on the expected function

Advantages Simple design and maintenance No waste stream Heat, ozone and chemical sanitization are possible Disadvantages Can be used only as part of a total microbial control plan No ion or endotoxin removal No disinfection residual Particulate can shield organism from UV light Dead organism are not removed from the water

254 nm units are used for limiting bacteria contamination, breaking the microorganism outer membrane to modify the DNA in order to avoid the replication

185 nm units are used for TOC (Total Organic Carbon) reduction

48
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION WFI

49
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

50
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

Distillation normally is used as the final processing step for quality WFI system To select appropriate technologies, the manufacturer of products should first consider where the products will be distributed and what regulations are applicable to those market Distillation technologies require adequate pre-treatment to prevent/minimize corrosion and scale formation and allow final unit operations to meet compendial requirements WFI should be produced using different technologies as Multiple Effect Water Still (ME) or Vapor Compression Still (VC), but normally the production steps are Water is evaporated, producing steam By means separation devices, steam will be disengage from water droplets that contain dissolved solids, non-volatiles and other impurities Pure Steam is condensed into WFI

51
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

BASIS FOR ECONOMIC COMPARISON


The three primary factors affecting the operating costs of any still design are
INDUSTRIAL STEAM

COOLANT CONSUMPTION

ELECTRICITY

Using these estimates and the local cost of each utility, expense can be projected based on anticipation volume. The appropriate selection should be based on a comparison of operating cost versus capital cost

52
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

CONTRUCTION MATERIALS and SURFACE FINISHING


The recommended material for the equipment is Stainless Steel AISI 316L, finishing Ra 0,6 m, polished and passivated, while for gasket materials should be suitable for the maximum temperature to which they will be exposed, normally silicone or PTFE FDA approved gasket are used

53
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS


CONDENSATE DISCHARGE

WATER FOR INJECTION (WFI)


PURE STEAM

PURE STEAM CONDENSE

COOLING WATER

WFI PURE STEAM

OFF-SPEC WFI

INDUSTRIA L STEAM

FEEDING PURIFIED WATER

CONDENSATE
CONDENSATE LIQUID DISCHARGE

54
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

FEED WATER PRE-HEATER and FINAL CONDENSER


In order to reduce the energy consumption and operation costs, two DTS Heat Exchanger are installed before the first distillation column. The exchanger recover and transfer the heat from produced Pure Steam and WFI to feed water

1st condenser Cool side : Feed Water Heat side : Pure Steam 2nd condenser Cool side : Cooling Water Heat side : Pure Steam

Pre-Heater Cool side : Feed Water Heat side : Condensate Discharge

55
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

FIRST DISTILLATION COLUMN

Double Tube Sheet (DTS) design to safety the separation between aseptic product and industrial steam High steam velocity design

Efficient heat transfer design


Automatic control of feed water flow rate by means dedicated 4-20 mA level transmitter Automatic control and regulation of produced WFI according to WFI Storage Tank inside level Less thermal variations More continuatives operation

56
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

SECOND and OTHER DISTILLATION COLUMN


Each column use as heating steam the pure steam coming from the previous column High steam velocity design Efficient heat transfer design Single tube design, because heating steam is pure steam Automatic control of feed water flow rate by means dedicated 4-20 mA level transmitter Every added column increase capital cost but reduce required industrial steam and cooling water amount (operating costs)
Plant steam pressure 8 bar 175C Capacit y lt/h 4 Steam Consumption kg/h Effects number 5 6 7

2.300

783

630

528

456

57
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

CYCLONE SEPARATION SYSTEM


The heart of WFI production system is the separation of water droplets containing contaminants from the pure steam, by means a cyclone system installed inside each evaporation column. Two basic principle are used for this process: High Steam speed creating centrifugal forces that separate any entrained water particles and throw them to the outer wall of separator to drain. Double 180 turns: The pure steam flow direction is forced to double 180 turns inducing gravity separation of larger water droplets.

58
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

VAPOR COMPRESSION DISTILLATION


Two circuits supplied by the same water, primary circuit produces distillate from feed water while secondary circuit is responsible for the heat recovery. The feed water enters the system and is heated up in the heat exchanger by the leaving distillate. The energy for evaporation is delivered by the steam of secondary circuit which condensate in the heat exchanger. Large evaporation produces dry steam nearly without droplets; this steam passes the cyclone for last droplets removing by means centrifugal force. The clean steam reaches the condenser and condenses to sterile distillation. The water of secondary circuit evaporates, is taken in by pump and raised to an higher pressure and temperature thus the steam can be used as heating medium for feed water evaporation.

59
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

FINAL TREATMENT OPTIONS

WATER FOR INJECTION (WFI)

QUALITY DESIGN OF MATERIAL, FINISHING, CONSTRUCTION AND PROCESS CONTROL, INCLUDED IN THERMOCOMPRESSION WATER STILL SYSTEM
Quenched Waste System SS 304 L cooling spray nozzles, automatic cooling water valve All the SS 316 L material in contact with pure steam have a roughness < 0,6 m Ra All tubing and fittings are welded by orbital machine, wherever technically possible. Welding map and welding report are included Support Frame All components are assembled on a SS 304 Support Frame

SS 316 L Finishing Surfaces

Welding piping, Welding Map and Welding Report

60

INTRODUCTION

4. STORAGE AND DISTRIBUTION

61
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


Distribution Loop
transport the water to use points (POUs) at the required flow, temperature and pressure.

Storage Tank
supply the facility peak consumptions without the necessity of over sizing the purification system.

62
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

63
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

STORAGE TANK
ADVANTAGES
Reserve capacity during purification outage Atmospheric air break for loop return Service of upstream water purification equipment Minimize purification system instantaneous demand capacity Contact tank for ozone sanitization

POTENTIAL DISADVANTAGES
Storage tank capital costs Associated equipment capital costs (pumps, vent filter, instrumentation, etc...) Usually less than water purification equipment size increasing to handle the peak demand

64
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


In order to prevent biofilm contamination, periodic sanitization and continuous circulation of the water are needed.

A tank spray ball is recommended to allow the wetting of the entire internal tank surface.

65
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

TANKS SIZING and DESIGN CONSIDERATION


Criteria affecting storage capacity are users existing and future demand, amount of use, duration, timing and number of POUs simultaneously opened Vessels should be designed and installed using appropriate standards that dont compromise the water quality or system operation Horizontal tanks may be used to address space issues, while vertical orientation is the most common based on the following advantages: Lower cost Less dead volume Simpler spray ball design Less floor space require

66
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

67
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

PUMPS
Sanitary centrifugal pumps are commonly employed and designed on flow, pressure, temperature and velocity.
Frequency control device that control the pump motor speed, may be used to maintain a constant internal loop speed in every operating condition

VENT FILTERS
The tank should be vented to allow filling and emptying, and a filter should be used at the vent to avoid microbial contamination. Typically are made in hydrophobic PTFE, PP, or PVDF to prevent wetting. Filters should be capable of withstanding sanitization and sized based on vessel design characteristics

HEAT EXCHANGER
Heat Exchanger equipment is used to heat or cool distributed water to desirable levels or to maintain temperatures.
Equipment part in contact with distributed water should be specified with appropriate materials, finishes and connections.

68
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

DISTRIBUTION LOOP
TUBAZIONI Attrezzature farmaceutiche e sistemi di tubazioni per il PW, HPW, WFI e la distribuzione del vapore puro, devono in acciaio inox AISI 316L, resistente alla corrosione, necessaria a soddisfare le condizioni di funzionamento e metodi di sanificazione. La produzione dei tubi e la installazione devono rispondere alle specifiche norme (ad esempio, ASTM, ASME BPE, ISO, DIN, SMS, BS, JIS-G), oltre ad altri requisiti (21 CFR 211.65). Saldatura automatica il metodo preferito per unire i sistemi di tubazioni di elevata purezza, a causa del maggiore controllo dei parametri critici di saldatura , tuttavia saldatura manuale pu essere richiesto e utilizzato in situazioni specifiche.. I sistemi di stoccaggio e di distribuzione devono essere installati in conformit con cGMP. VALVOLE Valvole a membrana generalmente sono utilizzati in sistemi ad elevata purezza. Altri tipi di valvole, quali valvole a sfera e valvole a spillo , in genere non vengono utilizzati.

69
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


LOOP DIMENSIONAMENTO Il flusso di acqua nella tubazione deve essere di tipo turbolento per controllare lo sviluppo del biofilm sulla parete tubazione. La capacit del sistema dovrebbe essere tale che la quantit desiderata di acqua pu essere utilizzata in qualsiasi momento senza rischiare la perdita di pressione di ritorno. Tipicamente il dimensionamento del loop deve garantire la velocit interna nella tubazione in un range 1 3 m / sec. In ogni condizione di lavoro. PROGETTAZIONE CONSIDERAZIONE considerato pratica comune per consentire il completo svuotamento del circuito di distribuzione per evitare il ristagno di acqua. Rami morti (dead leg) dovrebbero essere ridotti al minimo o eliminati. Una condizione turbolenta pu essere mantenuto se la lunghezza dei tronchetti limitata,non superiore a 3 diametri.

70
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


STRUMENTI Strumentazione appropriata dovrebbe garantire il corretto monitoraggio di un sistema di acqua ad elevata purezza. I componenti possono variare da indicatori visivi locali di dispositivi in grado di integrazione con i sistemi elettronici che offrono il controllo, allarme, trend. I parametri tipici monitorati in acqua farmaceutica sono temperatura, pressione, livello del serbatoio e della conducibilit. Ulteriori parametri possono includere flusso, la velocit della pompa e TOC.

71
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


CONSIDERAZIONI GENERALI Numerosi criteri devono essere considerati quando si valuta progetti alternativi per i sistemi di stoccaggio e distribuzione. I vantaggi / svantaggi di progettazione devono essere conformi ai requisiti utente per l'acqua. La progettazione ottimale di un deposito di acqua farmaceutica e sistema di distribuzione dovrebbe includere le seguenti voci: - Mantenere la qualit chimica e microbica delle acque entro limiti accettabili; - Ridurre al minimo le condizioni e le posizioni che favoriscono la crescita microbica; - Garantire la necessaria portata istantanea a pi punti di utilizzo.; - Ridurre al minimo di capitale e costi operativi; - Considerazione la possibilit di una futura espansione.

72
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


Continuous Circulation?

Distribution Decision Flowchart


Branched/ One Way Distribution

No

Yes

Ozonated Storage and Distribution

Ozone
POU Temperature Required?

Ambient Only

Method of Sanitization?

Heat

Hot or Multiple Temperatures

Chemical
Ambient or Reduced Temperature Storage and Distribution

Hot Storage, Cooled and Reheated Distribution OR Hot Storage, Cooled Bypass Circulating Distribution OR Ambient or Reduced Temperature Storage and Distribution

Hot Usage Only?

Yes

Hot Storage, Hot Distribution

or

Primary/Secondary Distribution (Hot)

No
Limited Quantity of Cooled Use Point

Yes

Hot Distribution, Cooled Branch Use Point, Heat Sanitized

or

Hot Distribution, Cooled Use Point, Slip Stream

No
Hot Distribution, Cooled Sub-Loop

or

Primary/Secondary Distribution (cooled)

or

Parallel Distribution Loops (cooled)

73
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


PW cold Storage and Distribution with Continuous Polishing - Heat sanitizable

Advantages Water quality continuously maintained Can maintain water quality stored over extended periods of low or no use

74
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


Ozonated PW Storage and Distribution

Advantages
Compatible non-metallic material of construction may be considered Excellent microbial control No heat hazards during sanitization Tank and pump continuously sanitized Low cost of operation Return water sanitized in tank Short sanitization time

75
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


WFI Hot Distribution with cooled Use Point, Slip-Stream

Advantages
Can be used for single or multiple cooled, localized use point Use point can be hot or cooled Lower energy consumption than cooling entire loop Continuous flow through slip-stream

76
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


The same configuration can be applied for a cold PW Storage and Distribution system with heated POUs and Thermal Sanitization. The PW should be maintained <15C and greater turbulence in order to minimize bacteria growth and biofilm contamination

77
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

USE POINTS (POUs) CONFIGURATION


characterized for each use point. Each POU should be identified with following proper values Unique identifier (tag) Maximum instantaneous flow rate Periodic consumption requirements (e.g. Daily, weekly) and duration Pressure requirement Temperature requirement Method of delivery (automatic or manual)

In general terms, FLOW RATE is primarily used for sizing distribution lines

78
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

HOW TO DRAWN THE WATER?


The distribution loop topic key in design considerations is minimized, or eliminated where possible, the DEADLEGS. A turbulent condition may be maintained in short dead ended pipe stubs. There are two valve configuration to solve this problem

MINIMUM DEAD LEG (standard valve configuration)

ZERO DEAD LEG VALVE

79
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

The standard valves configuration (Minimum dead leg) will be installed at the minimum distance from the distribution loop in order to minimize the dead legs

The user points valves type butt welds, will be installed directly on the main loop piping in order to avoid dead legs.

80
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION


CARICA MICROBICA E BIOFILM CI SONO PROVE SCIENTIFICHE CHE I BATTERI PREFERISCONO VIVERE IN BIOFILM,

Estese indagini su sistemi acquatici hanno dimostrato che oltre il 99% di tutta lattivit microbica avviene in biofilm.Il biofilm definito come cellule batteriche aderenti tra loro e / o alle superfici di contatto e sono ricoperte da una sostanza vischiosa (lipopolisaccaride), che agisce come uno scudo, proteggendo il biofilm da attacchi fisici e chimici. Lo spessore di un biofilm essenzialmente funzione di: - la concentrazione di nutrienti disponibili - velocit dellacqua - regime biocida, - pratiche di sanificazione, ecc

81
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

STRATEGY APPROACHES TO CONTROL BIOFILM


In order to maintain low the biofilm level in compendial water the combination of the following strategies should be considered:
1. Minimization of nutrient concentration in the PW compendial TOC less 100ppb 2. Selection material with internal finishing less 0.6 m Ra to make cleaning easier 3. Maintain high flow rate in the distribution piping > 1m/sec and turbulent flow Reynolds N > 10.000 4. Compendial Water Temperature heated > 85C (WFI) or cooled < 15C (PW) 5. Install U.V. light 254 nm on PW loop 6. Design Continuous PW Storage Tank sanitization by Ozone (O3) and weekly extension of Ozone sanitization to the PW distribution loop 7. Proceed on intermittent sterilization (121C) of WFI storage and distribution loop

82
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

STORAGE AND DISTRIBUTION

STRATEGY APPROACHES TO CONTROL BIOFILM


Nota: Sterilizzazione del biofilm con, per esempio, il vapore uccidere tutti i batteri presenti, tuttavia, il vapore non rimuove completamente il biofilm (all'occorrenza). Tuttavia, l'asportazione di un biofilm pu essere molto importante, poi che evitta che divente nutriente a sua volta per i nuovi batteri invasori.
sec-min sec-min hours-days days-years

I vantaggi di biocidi (ad esempio, l'ozono) hanno un doppio effetto : indeboliscono le forze dinamica di legame dei batteri tra loro ed alla superficie, riducendo in tal modo le forze di taglio necessari per la loro rimozione del biofilm stesso

83

INTRODUCTION
5. VALIDATION ACTIVITIES QUALIFICA DI COMPENDIA WATER

84

VALIDATION ACTIVITIES
LA VALIDAZIONE DI UN IMPIANTO cGMP COMPLIANT DEVE STRETTAMENTE SEGUIRE LE SEQUENZE DEFINITE DALLE AUTORITA DI RIFERIMENTO: Usp 35 Eur Pharmacopeias 7.0 cGMP- requirements Guidelines of the drug control authorities (FDA) Gamp 5

WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

LA QUALIFICA DEL SISTEMA ACQUA Le procedure di qualificazione hanno lo scopo di dimostrare che il sistema messo in esercizio produce in modo consistente acqua della qualit di specifica, nelle differenti condizioni, operando secondo le procedure definite. Le procedure di qualifica includono le seguenti fasi: Redazione dei Protocolli di Installation Qualification (IQ); Redazione dei Protocolli di Operational Qualification (OQ); Redazione dei Protocolli di Performance Qualification (PQ).

85

Qualifica - IQ
1.1 Qualifica di Installazione IQ Lattivit di IQ consiste nella verifica che il nuovo impianto realizzato, risulti conforme ai documenti di progetto e sia stato correttamente realizzato in accordo con le specifiche di progetto. Il protocollo di IQ dovr indicare con chiarezza e sinteticit le attivit previste per la qualifica dellinstallazione, definendo lo scopo, i prerequisiti, il metodo, le attivit da svolgere in campo, le responsabilit e i criteri di accettabilit. Al termine della qualifica di installazione, ad ogni protocollo dovr corrispondere: Il rapporto della documentazione controllata (disegni, specifiche, schemi) I rapporti per i controlli visivi di installazione relativi alla corrispondenza tra i documenti di progetto e gli impianti realizzati I rapporti relativi ai test fisici di post-installazione(es. test hardware sistemi computerizzati, test di pressatura idraulica, passivazione) Il rapporto finale della qualifica con lelenco di tutti i rapporti e lelenco delle deficienze riscontrate, con le relative azioni di correzione messe in atto

86

Qualifica - OQ
1.2 Qualifica di Funzionamento OQ La fase di OQ consiste nella verifica che i sistemi funzionino correttamente e garantiscano risultati in totale accordo alle specifiche funzionali di progetto. Prerequisito per lesecuzione della fase di OQ il completamento positivo della fase IQ. Il protocollo OQ dovr indicare con chiarezza e sinteticit le attivit previste per la qualifica del funzionamento degli impianti, definendo lo scopo, i prerequisiti, il metodo, le azioni, i criteri de accettabilit, il numero di ripetizioni o la durata delle prove e la strumentazione da utilizzarsi. Ad ogni protocollo di IQ dovranno corrispondere: I rapporti relativi alle calibrazioni degli strumenti critici (Instruments calibration Reports) I verbali con i dati relativi alle prove di funzionamento del sistema

87

Qualifica - PQ
1.3 Qualifica di Performance - PQ La qualifica di performance si suddivide in tre fasi con obiettivi differenti:
Fase Obiettivi Durata della Fase

Sviluppare gli appositi range operativi Sviluppare e finalizzare le procedure operative, per il cleaning e per la manutenzione Dimostrare che il sistema in grado di produrre acqua della qualit richiesta Dimostrare che limpianto performa allinterno dei range prestabiliti Dimostrare la coerenza tra la qualit dellacqua prodotta e la qualit richiesta Dimostrare che limpianto in grado di mantenere in maniera stabile e a lungo termine i parametri di progetto

24 settimane

24 settimane

1 anno

88

Criteri di Accettazione
1.4 Criteri di Accettazione FASE 1 e 2 I risultati ottenuti dalla fase 2 di convalida dovranno rispecchiare landamento dei campionamenti di fase 1 dimostrando lalta qualit dellacqua prodotto dallapparecchio di generazione I parametri indagati dovranno essere conformi alle specifiche USP e EP e ai limiti b pi restrittivi definiti nel protocollo di convalida. Lacqua prodotta dallimpianto dovr dimostrarsi idonea allutilizzo produttivo. FASE 3 I risultati ottenuti dovranno rispecchiare landamento dei campionamenti di fase 2 dimostrando lalta qualit dellacqua prodotta. I parametri indagati dovranno essere conformi alle specifiche USP e EP e ai limiti pi restrittivi definiti nel protocollo di convalida. Lacqua prodotta dallimpianto dovr dimostrarsi idonea allutilizzo produttivo. Dopo le attivit di convalida vengono convalidate la frequenza delle attivit di sanitizzazione / sterilizzazione del reparto produzione, le frequenze delle attivit di sanitizzazione / sterilizzazione del reparto stoccaggio e distribuzione e vengono meglio precisati gli Alert e Action Limit.

89

INTRODUCTION

6. COMPARISON COMPENDIA

90
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

COMPARISON COMPENDIA

COMPARAZIONE COMPENDIAL WATER ANVISA versusUSP35 - EP7


USP 35
United States Pharmacopeia
Compendial Water

EP 7th Ed
European Pharmacopoeia
Purified Water Water for Injection Highy Purified Water 4.3 S/cm @ 20C 5.1 S/cm @ 25C
Multiple Effect Still Vapor Compression Still MANDATORY.

ANVISA
Agncia Nacional de Vigilncia Sanitria
Purified Water Water for Injection

Purified Water Water for Injection

PW Conductivity

1.1 S/cm @ 20C 1.3 S/cm @ 25C


Multiple Effect Still Vapor Compression Still Double Pass RO

1.1 S/cm @ 20C 1.3 S/cm @ 25C


Multiple Effect Still Vapor Compression Still RECOMMENDED

WFI Generation Methods

91
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

COMPARISON COMPENDIA

Highy Purified Water


The definition of HPW makes it an alternative to WFI in those processes where the quality of WFI is desirable, but not required.
The quality attributes of HPW are the same as the quality attributes of EP WFI, but distillation is not a required final treatment process. Typical production methods include one more unit process compared to production of PW Advantages: generally less expensive than WFI generally chemical free method generally low operating costs Disadvantages: cannot replace WFI in all applications, for ex.: large volume parenterals

92
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

COMPARISON COMPENDIA

WFI Generation Methods


Today the use of Reverse Osmosis to prepare WFI is considered acceptable by the USP but non by the EP

EP is mandactory and ANVISA Recommend that WFI to be prepared by distillation

THE MAJOR OBJECTION ARE:

RANGE of SEPARATION for Reverse Osmosis


VALIDATION and MAINTENANCE of devices MICROBIOLOGICAL ASPECTS Biofilm formation on both sides RO membranes

93
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

COMPARISON COMPENDIA

94
WORKSHOP May 20th 2013 WATER FOR PHARMACEUTICAL PURPOSES

COMPARISON COMPENDIA ANVISA

Você também pode gostar